Research Analysts Set Expectations for SGMO Q1 Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) – Equities research analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Sangamo Therapeutics in a report issued on Tuesday, May 26th. HC Wainwright analyst P. Trucchio anticipates that the biopharmaceutical company will post earnings of ($0.03) per share for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Sangamo Therapeutics’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Sangamo Therapeutics’ Q2 2027 earnings at ($0.02) EPS, Q3 2027 earnings at $0.00 EPS and Q4 2027 earnings at $0.00 EPS.

A number of other equities research analysts have also recently weighed in on SGMO. Wall Street Zen cut Sangamo Therapeutics to a “strong sell” rating in a research note on Saturday, January 31st. Zacks Research cut Sangamo Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Thursday, April 16th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Sangamo Therapeutics currently has an average rating of “Reduce” and a consensus target price of $5.50.

Sangamo Therapeutics Trading Up 6.2%

Shares of NASDAQ SGMO opened at $0.19 on Wednesday. Sangamo Therapeutics has a twelve month low of $0.10 and a twelve month high of $0.77. The stock has a 50 day moving average of $0.23 and a two-hundred day moving average of $0.36. The stock has a market cap of $76.68 million, a P/E ratio of -0.42 and a beta of 1.04.

Insider Activity at Sangamo Therapeutics

In other news, SVP Nathalie Dubois-Stringfellow sold 345,942 shares of the company’s stock in a transaction that occurred on Tuesday, April 21st. The stock was sold at an average price of $0.26, for a total transaction of $89,944.92. Following the completion of the sale, the senior vice president owned 332,769 shares in the company, valued at $86,519.94. This represents a 50.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Sangamo Therapeutics

Several large investors have recently modified their holdings of the stock. Bank of America Corp DE raised its stake in shares of Sangamo Therapeutics by 1,856.1% during the first quarter. Bank of America Corp DE now owns 1,838,390 shares of the biopharmaceutical company’s stock worth $452,000 after purchasing an additional 1,744,406 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Sangamo Therapeutics during the fourth quarter worth approximately $56,000. Invesco Ltd. raised its stake in shares of Sangamo Therapeutics by 23.7% during the fourth quarter. Invesco Ltd. now owns 1,000,292 shares of the biopharmaceutical company’s stock worth $420,000 after purchasing an additional 191,561 shares during the last quarter. Oracle Investment Management Inc. raised its stake in shares of Sangamo Therapeutics by 3.1% during the fourth quarter. Oracle Investment Management Inc. now owns 1,035,742 shares of the biopharmaceutical company’s stock worth $435,000 after purchasing an additional 31,018 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Sangamo Therapeutics during the fourth quarter worth approximately $77,000. Hedge funds and other institutional investors own 56.92% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.